Survey
Survey on Desmoid Tumors and Ogsiveo March 2025
Ticker(s): SWTXThe survey results include 10 physicians that manage 2 or more patients with Desmoid Tumors.
How many patients with Desmoid Tumors do you manage?
Are you familiar with Ogsiveo (nirogacestat) and data to date? Yes/No
What is the male/female percentage (%) breakdown of your [X] Desmoid patients?
- Male
- Female
Of your male patients, how many are on Ogsiveo?
Of your female patients, what percentage (%) are of childbearing age?
Of your female patients, how many are on Ogsiveo?
Of your female patients on Ogsiveo, what % are not concerned about ovarian toxicity (ex. not planning on having any more children)?
Of your female patients of childbearing age who are concerned about ovarian toxicity (OT), how many are still on Ogsiveo?
Regarding your [X] female patients of childbearing age who are concerned about ovarian toxicity and still on Ogsiveo, how will this risk be addressed (ex. discontinue use prior to conceiving, other fertility preservation, etc)?
Roughly what percentage (%) of your patients that started Ogsiveo have discontinued Ogsiveo?
What reasons are cited for discontinuing the treatment?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
